$KA News

Last published 2y ago

2y agoKAKineta Reopens Enrollment for the VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor CancerGlobeNewswireEffective immediately, clinical sites in the VISTA-101 Phase 1/ Phase 2 clinical trial can resume screening of patients for enrollment in the clinical study 30 patients have been enrolled in the clinical trial to
2y agoKTRA KATuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor CancerPR NewswireTuHURA Biosciences, Inc. ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to...
2y agoKAKineta Announces Exclusivity and Right of First Offer Agreement for its VISTA blocking antibody with TuHURA BiosciencesGlobeNewswireTuHURA has an exclusive right to negotiate to acquire Kineta's KVA12123 Immuno-Oncology Drug Program Kineta will receive a $5 million Nonrefundable Payment from TuHURA KVA12123 is currently in a Phase 1/Phase 2
2y agoKTRA KATuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint InhibitorPR NewswireTuHURA Biosciences, Inc. ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to...
2y agoKAKineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate ActivitiesGlobeNewswirePartial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts Favorable clinical safety and tolerability profile observed with no dose limiting toxicities
2y agoKAKineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical TrialGlobeNewswirePartial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts Favorable clinical safety and tolerability profile observed with no dose limiting toxicities
2y agoKAKineta Reports Full Year 2023 Financial Results and Provides Corporate UpdateGlobeNewswirePartial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts in the VISTA-101 trial No dose limiting toxicities observed at any dose level in the
2y agoKAKVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data ReportedGlobeNewswirePartial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohortsNo dose limiting toxicities observed at any dose levelCleared fifth of six monotherapy cohorts
2y agoKAKineta Announces Restructuring and Exploration of Strategic AlternativesGlobeNewswireSEATTLE, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (NASDAQ:KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance,
2y agoKAKineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery SymposiumGlobeNewswireSEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (NASDAQ:KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance,
2y agoKAKineta to Present at Upcoming Investor ConferencesGlobeNewswireSEATTLE, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (NASDAQ:KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance,
2y agoKAKineta to Participate in H.C. Wainwright Virtual @Home Fireside Chat SeriesGlobeNewswireSEATTLE, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (NASDAQ:KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance,
2y agoKAKineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid TumorsGlobeNewswireCleared First Four Monotherapy Doses and Initial Combination Cohort with No Dose Limiting Toxicities at any Dose Level KVA12123 Monotherapy Demonstrated Dose Proportional Induction of Pro-inflammatory Biomarkers
2y agoKAKineta to Participate in the 13th Annual LifeSci Partners Corporate Access EventGlobeNewswireSEATTLE, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (NASDAQ:KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance,
2y agoKAKineta Publishes Preclinical Data Demonstrating the Potential of Anti-VISTA Antibody KVA12123 as an Immunomodulatory Therapy for CancerGlobeNewswireVISTA Blocking KVA12123 Monoclonal Antibody (mAb) Engineered to Provide Strong Single Agent Anti-Tumor Activity While Minimizing Cytokine Related Adverse Events KVA12123 recognizes a unique VISTA epitope and binds at
2y agoKAKineta to Present at the Life Sciences Investor Forum December 14thGlobeNewswireSEATTLE, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (NASDAQ:KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance,
2y agoKAKineta to Host KOL Event to Review New Data from VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors on December 5, 2023GlobeNewswireSEATTLE, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (NASDAQ:KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance,
3y agoKAKineta to Present at the 5th Annual Macrophage-Directed Therapies SummitGlobeNewswireSEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (NASDAQ:KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance,
3y agoKAKineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer's (SITC) 38th Annual MeetingGlobeNewswireFavorable Clinical Safety and Tolerability Profile Observed with No Evidence of CRS-associated Cytokines Achieved Greater Than Dose-Proportional Pharmacokinetics Biomarker Results Demonstrate Robust VISTA Target
3y agoKAKineta Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewswireAnnounced positive KVA12123 monotherapy safety data from its ongoing phase 1/2 VISTA-101 clinical trial Enrolled the first patient of KVA12123 in combination with pembrolizumab in patients with advanced solid tumors
3y agoKAKineta Presents New Preclinical Data on Lead Anti-CD27 Monoclonal Antibody at the Society for Immunotherapy of Cancer's (SITC) 38th Annual MeetingGlobeNewswireLead Anti-CD27 Monoclonal Antibody Showed High Binding Affinity and Specificity Drives Strong T Cell Activation and Proliferation as well as NK Cell Activation Demonstrated In Vivo Antitumor Efficacy as a Single Agent
3y agoKAKineta Announces First Patient Dosed in Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid TumorsGlobeNewswireThe Combination Arm (Part B) of the Phase 1/2 Clinical Trial Builds Upon the Initial Safety, Tolerability and Pharmacokinetic Data of KVA12123 in the Monotherapy Arm (Part A) Initial Combination Therapy Clinical
3y agoKAKineta Announces KVA12123 and Anti-CD27 Agonist Antibody Abstracts Accepted for Poster Presentations at Society for Immunotherapy of Cancer (SITC) 2023GlobeNewswireSEATTLE, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (NASDAQ:KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance,
3y agoKAKineta to Present Preclinical Data on VISTA Blocking KVA12123 at Immuno US 2023GlobeNewswireSEATTLE, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (NASDAQ:KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance,
3y agoKAKineta, Inc. Announces Closing of $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesGlobeNewswireSEATTLE, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (NASDAQ:KA) (the "Company" or "Kineta"), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address
3y agoKAKineta Presents New Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and ImmunotherapyGlobeNewswireSEATTLE, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (NASDAQ:KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance,
3y agoKAKineta, Inc. Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesGlobeNewswireSEATTLE, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (NASDAQ:KA) (the "Company" or "Kineta"), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address
3y agoKAKineta Announces Positive KVA12123 Monotherapy Safety and Biomarker Data from its Ongoing Phase 1/2 VISTA-101 Clinical TrialGlobeNewswireCleared First Three Monotherapy Cohorts with No Dose Limiting Toxicity and No Consistent Pattern of Adverse Events at any Dose Level >90% VISTA Receptor Occupancy Observed in the 30 mg Dosing Cohort VISTA
3y agoKAKineta Announces Participation at October Investor ConferencesGlobeNewswireSEATTLE, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (NASDAQ:KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance,
3y agoKAKineta to Present New Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and ImmunotherapyGlobeNewswireSEATTLE, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (NASDAQ:KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance,
3y agoKAKineta Announces New Research Agreement to Evaluate VISTA Biomarker ExpressionGlobeNewswireSEATTLE, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (NASDAQ:KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance,
3y agoKAKineta to Participate in Upcoming Investor ConferencesGlobeNewswireSEATTLE, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (NASDAQ:KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance,
3y agoKAKineta Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewswireInitial Clinical Data Readout from Ongoing Phase 1/2 Study of VISTA-Targeting KVA12123 in Advanced Solid Tumors Anticipated by End of 2023 Received $5 Million Research and Development Collaboration Milestone Payment
3y agoAPRE KA PHAR XFORPharming to nominate industry leader Dr. Richard Peters as new Chairman of the BoardPR NewswireLEIDEN, The Netherlands, July 18, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) announces today that the Board of Directors has nominated Dr. Richard Peters to
3y agoKAKineta to Receive $5 Million Milestone Payment from MerckGlobeNewswireSEATTLE, June 29, 2023 (GLOBE NEWSWIRE) -- (June 29, 2023) Kineta, Inc. (NASDAQ:KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune
3y agoABBV ABOS KAKineta Expands Board of Directors with Biotech Industry Leaders Kim Drapkin and Scott DyllaGlobeNewswireSEATTLE, June 28, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (NASDAQ:KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance,
3y agoKAKineta Set to Join Russell Microcap® IndexGlobeNewswireSEATTLE, May 24, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (NASDAQ:KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance,
3y agoKAKineta to Present at Jefferies Healthcare ConferenceGlobeNewswireSEATTLE, May 23, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (NASDAQ:KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance,
3y agoKAKineta Reports First Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewswireDosed First Patient in Phase 1/2 Clinical Study of VISTA-Targeting KVA12123 in Advanced Solid Tumors Initial KVA12123 Clinical Data Readout Anticipated by End of 2023 Closed $6 Million Registered Direct Offering
3y agoKAKineta, Inc. Announces Closing of $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesGlobeNewswireSEATTLE, April 24, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (NASDAQ:KA) (the "Company" or "Kineta"), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address
3y agoKAKineta, Inc. Announces $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesGlobeNewswireSEATTLE, April 20, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (NASDAQ:KA) (the "Company" or "Kineta"), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address
3y agoKAKineta Unveils New VISTA Biomarker Data and KVA12123 Phase 1/2 Clinical Trial Update at AACR Annual Meeting 2023GlobeNewswireSEATTLE, April 17, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (NASDAQ:KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance,
3y agoKAKineta Announces First Patient Dosed in Phase 1/2 Clinical Study of KVA12123 for Advanced Solid TumorsGlobeNewswireVISTA blocking immunotherapy engineered to address immunosuppression in the tumor microenvironment (TME) Phase 1 initial data readout anticipated by end of 2023 SEATTLE, April 12, 2023 (GLOBE NEWSWIRE) -- Kineta,
3y agoKAKineta to Present at 22nd Annual Needham Healthcare ConferenceGlobeNewswireSEATTLE, April 03, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (NASDAQ:KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance,
3y agoKAKineta Reports Full Year 2022 Financial Results and Provides Corporate UpdateGlobeNewswireOpened a Phase 1/2 clinical study of VISTA Targeting KVA12123 for Advanced Solid Tumors Initial Data Readout Anticipated by End of 2023 Successfully Completed the Reverse Merger with Nasdaq-listed Yumanity
3y agoKAKineta to Present VISTA Biomarker Data at AACR Annual Meeting 2023GlobeNewswireSEATTLE, March 22, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (NASDAQ:KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance,
3y agoKAKineta to Present at the Oppenheimer 33rd Annual Healthcare ConferenceGlobeNewswireSEATTLE, March 08, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (NASDAQ:KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance,
3y agoKAKineta to Host Key Opinion Leader Event on KVA12123: VISTA as an Immuno-Oncology TargetGlobeNewswireSEATTLE, March 06, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (NASDAQ:KA), a clinical-stage biotechnology company focused on developing next-generation immunotherapies to address cancer immune resistance, announced today it
3y agoKAKineta Appoints Internationally-Renowned Clinical Immuno-oncology Experts to its Scientific Advisory BoardGlobeNewswireSEATTLE, March 01, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (NASDAQ:KA), a clinical-stage biotechnology company focused on developing next-generation immunotherapies to address cancer immune resistance, announced today